STOCK TITAN

Director at Standard BioTools (LAB) takes RSUs instead of cash pay

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cox Troy reported acquisition or exercise transactions in this Form 4 filing.

STANDARD BIOTOOLS INC. director Troy Cox reported an award of 57,264 restricted stock units representing common stock on February 26, 2026. These RSUs were valued at $1.17 per share for reporting purposes and bring his directly held stake to 376,586 shares after the grant.

The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service through each vesting date. Cox elected to receive this equity grant instead of $67,000 in cash compensation for his board role.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cox Troy

(Last) (First) (Middle)
C/O STANDARD BIOTOOLS INC.
50 MILK STREET, 10TH FLOOR

(Street)
BOSTON MA 02109

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/26/2026 A 57,264(1) A $1.17 376,586(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2026, subject to the Reporting Person's continued service through the applicable vesting date.
2. The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $67,000 in cash compensation for services as a board member.
/s/ Troy Cox by Tomone Tanaka, Attorney-in-Fact 03/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Troy Cox report in his latest Form 4 for LAB?

Troy Cox reported receiving 57,264 restricted stock units representing common stock of STANDARD BIOTOOLS INC. (LAB). The grant reflects equity compensation for his board service and increases his directly held stake to 376,586 shares after the award.

How do Troy Cox’s new RSUs for LAB vest over time?

The 57,264 RSUs granted to Troy Cox vest in four equal 25% installments during 2026. Vesting occurs on the last day of the last month of each fiscal quarter, provided he continues serving on the board through each applicable vesting date.

Why did Troy Cox receive RSUs instead of cash from STANDARD BIOTOOLS (LAB)?

Troy Cox elected to receive RSUs in lieu of $67,000 in cash compensation for his board services. This choice shifts his compensation toward equity, further aligning his interests with shareholders through additional stock-based incentives rather than immediate cash payment.

What is Troy Cox’s total LAB share ownership after this Form 4 transaction?

After the reported RSU grant, Troy Cox directly holds 376,586 shares of STANDARD BIOTOOLS INC. common stock. This figure includes the newly awarded 57,264 RSUs, which vest over 2026 subject to his continued service on the company’s board.

At what price were Troy Cox’s new LAB RSUs reported for valuation purposes?

The 57,264 RSUs granted to Troy Cox were reported at $1.17 per share for valuation purposes. This price is used solely for disclosure and accounting in the Form 4, reflecting the reference value of the equity-based compensation award.

STANDARD BIOTOOLS INC

NASDAQ:LAB

LAB Rankings

LAB Latest News

LAB Latest SEC Filings

LAB Stock Data

434.56M
374.82M
Medical Devices
Laboratory Analytical Instruments
Link
United States
SOUTH SAN FRANCISCO